For Immediate Release
Chicago, IL – May 15, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mastercard (MA - Free Report) , NVIDIA (NVDA - Free Report) , Danaher (DHR - Free Report) , Automatic Data Processing (ADP - Free Report) and Altria (MO - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for Mastercard, NVIDIA and Danaher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard, NVIDIA and Danaher. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Strong-Buy ranked Mastercard’s shares have increased 63.6% over the last year, significantly outperforming the Zacks Financial Transaction Services industry’s gain of 37.4% during the same period. Mastercard’s earnings beat expectations and surged 43% year over year. Better-than-expected results were primarily backed by higher switched transactions, increase in cross-border volume and gross dollar volume as well as gains from acquisitions.
The Zacks analyst thinks the company is well placed for growth, given its solid market position, ongoing expansion and digital initiatives plus significant opportunities from the secular shift toward electronic payments. The buyouts of VocaLink and NuData Security complement the company’s efforts to participate in new payment flows and enhance its safety and security offerings.
The stock has seen the Zacks Consensus Estimate for current-year earnings being revised upward over the last 30 days. However, escalating costs continue to bother. Also, higher incentives and rewards will put pressure on its bottom line.
(You can read the full research report on Mastercard here >>>).
Shares of NVIDIA have surged in the last one year, gaining +89.5% versus the Zacks General Semiconductor industry’s +57.4% gain, thanks to the company’s positive record of earnings surprises in the recent quarters. NVIDIA posted a stellar first quarter and provided encouraging second-quarter fiscal 2019 revenue guidance.
Also, the company registered year-over-year growth on both the counts, primarily stemming from growth across all four platforms. Also, higher-than-anticipated demand for its gaming chips helped drive the encouraging results. Furthermore, the Zacks analyst thinks NVIDIA’s innovative product pipeline and strength in gaming and high-end notebook GPUs keep it well positioned.
Higher adoption of NVIDIA’s Volta processors is also likely to act as a catalyst in the near term. Nevertheless, a recent development like suspension of test drives for all its driverless vehicles and likely sluggish demand from cryptocurrency miners leads to caution about its near-term performance.
(You can read the full research report on NVIDIA here >>>).
Buy-ranked Danaher’s shares have gained +10.1% over the past six months, outperforming the Zacks Diversified Operations industry, which has declined -5.5% over the same period. Danaher’s first-quarter 2018 adjusted earnings beat expectations by 6.5% and improved 16.5% year over year.
The company’s core revenue growth, margin expansion and earnings growth during the reported quarter came on the back of its operating culture DBS. The Zacks analyst is optimistic about the company’s core revenue and earnings growth, on the back of improving order trends and rising healthcare spending. Its recent acquisitions – Pall and Cepheid – are proving to be strong profit churners, and will boost core revenues in the quarters ahead.
This apart, the company’s continuous introduction of products enables it to penetrate new markets and gain competitive edge in existing ones. However, sluggish economic conditions across some key operating regions and unfavorable currency translations pose as significant headwinds.
(You can read the full research report on Danaher here >>>).
Other noteworthy reports we are featuring today include Automatic Data Processing and Altria.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.